Home LiteratureArticle Details
PMID: 33552277 Published · ppublish English Journal Article

B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma.

Oncology letters ·Vol. 21 ·No. 2 ·2021-02-00 ·Pages 159

Kong K, Zhao Y, Xia L, Jiang H, Xu M, Zheng J

Abstract

Pancreatic cancer, one of the most malignant gastrointestinal tumors, is prone to liver metastasis. However, due to the lack of appropriate and comprehensive diagnostic methods, it is difficult to accurately predict the survival outcomes. Therefore, there is a need to identify effective biomarkers, such as UDP-GlcNAc: βGal β-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3), that predict the survival outcome of patients with pancreatic cancer. In the present study, based on data from 171 cases of pancreatic cancer obtained from The Cancer Genome Atlas portal, the differential expression of mRNAs was screened by comparing cancerous tissues with adjacent tissues. Univariate Cox regression analysis demonstrated that B3GNT3 had prognostic capability and could be an independent prognostic factor for pancreatic adenocarcinoma (PAAD). Using the Tumor Immune Estimation Resource tool and Tumor-Immune System Interaction Database, a potential relationship between B3GNT3 expression and immune cell infiltration was identified in pancreatic carcinoma. Furthermore, 177 samples of pancreatic carcinoma were collected and the association of CD68 expression with B3GNT3 was assessed by immunohistochemical staining. B3GNT3 expression was associated with clinical outcomes in pancreatic carcinoma and related to infiltrating levels of immune cells, which indicated that B3GNT3 could be used as an immunotherapy target for PAAD.

Keywords
UDP-GlcNAc:βGal β-1 3-N-acetylglucosaminyltransferase 3 biomarker immune pancreatic cancer survival
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Kong Kaiwen
Department of Pathology, Changhai Hospital, Navy Medical University, Shanghai 200433, P.R. China.
Zhao Yuanyu
Department of Organ Transplantation, Changzheng Hospital, Navy Medical University, Shanghai 200433, P.R. China.
Xia Leilei
Department of Obstetrics and Gynecology, Changhai Hospital, Navy Medical University, Shanghai 200433, P.R. China.
Jiang Hui
Department of Pathology, Changhai Hospital, Navy Medical University, Shanghai 200433, P.R. China.
Xu Mingjuan
Department of Obstetrics and Gynecology, Changhai Hospital, Navy Medical University, Shanghai 200433, P.R. China.
Zheng Jianming
Department of Pathology, Changhai Hospital, Navy Medical University, Shanghai 200433, P.R. China.
References (32)
32 references, click to expand
  1. B3GNT3 expression suppresses cell migration and invasion and predicts favorable outcomes in neuroblastoma.
    Cancer Sci. 2013 Dec;104(12):1600-8 PMID: 24118321
  2. Wnt5a/CaMKII/ERK/CCL2 axis is required for tumor-associated macrophages to promote colorectal cancer progression.
    Int J Biol Sci. 2020 Feb 4;16(6):1023-1034 PMID: 32140070
  3. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
    Clin Cancer Res. 2020 Apr 15;26(8):1997-2010 PMID: 31964786
  4. Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family.
    J Biol Chem. 2001 Feb 2;276(5):3498-507 PMID: 11042166
  5. B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.
    PLoS One. 2015 Dec 28;10(12):e0144360 PMID: 26709519
  6. Pancreatic cancer.
    Lancet. 2020 Jun 27;395(10242):2008-2020 PMID: 32593337
  7. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
    JAMA Surg. 2018 Dec 1;153(12):e183617 PMID: 30285076
  8. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
    Mol Cancer. 2013 Jun 12;12:60 PMID: 23758976
  9. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
    Arch Pharm Res. 2016 Aug;39(8):1085-99 PMID: 27515050
  10. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer.
    Gastroenterology. 2003 Sep;125(3):891-905 PMID: 12949733
  11. Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS.
    Neurol Neuroimmunol Neuroinflamm. 2020 Apr 8;7(3): PMID: 32269065
  12. Estrogen receptor α promotes lung cancer cell invasion via increase of and cross-talk with infiltrated macrophages through the CCL2/CCR2/MMP9 and CXCL12/CXCR4 signaling pathways.
    Mol Oncol. 2020 Aug;14(8):1779-1799 PMID: 32356397
  13. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Lancet Oncol. 2020 Mar;21(3):e135-e145 PMID: 32135117
  14. Immunotherapy in pancreatic cancer and the importance of tumour testing.
    BMJ Case Rep. 2020 Jul 16;13(7): PMID: 32675128
  15. Investigation of ICOS, CD28 and CD80 polymorphisms with the risk of hepatocellular carcinoma: a case-control study in eastern Chinese population.
    Biosci Rep. 2019 Jul 5;39(7): PMID: 31235485
  16. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma.
    Genome Med. 2014 Dec 03;6(12):105 PMID: 25587357
  17. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.
    Blood. 2007 Dec 15;110(13):4455-63 PMID: 17827388
  18. The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.
    Dis Markers. 2015;2015:379568 PMID: 26294807
  19. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase.
    Cell. 2001 Jun 29;105(7):957-69 PMID: 11439191
  20. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.
    Cancer Immunol Res. 2019 Feb;7(2):257-268 PMID: 30659054
  21. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
    Cancer Immunol Res. 2014 Feb;2(2):167-76 PMID: 24778280
  22. B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.
    J Clin Pathol. 2018 Jul;71(7):642-647 PMID: 29483137
  23. TISIDB: an integrated repository portal for tumor-immune system interactions.
    Bioinformatics. 2019 Oct 15;35(20):4200-4202 PMID: 30903160
  24. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
    Mol Cancer. 2020 Feb 27;19(1):41 PMID: 32103760
  25. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
    Am J Cancer Res. 2020 Jul 01;10(7):1937-1953 PMID: 32774994
  26. Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen.
    Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):61-70 PMID: 10937051
  27. High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma.
    Sci Rep. 2019 Dec 27;9(1):20197 PMID: 31882943
  28. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
    Oncogene. 2003 Jan 23;22(3):319-29 PMID: 12545153
  29. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
    Cancer Cell. 2018 Feb 12;33(2):187-201.e10 PMID: 29438695
  30. Genomic cloning and expression of three murine UDP-galactose: beta-N-acetylglucosamine beta1,3-galactosyltransferase genes.
    J Biol Chem. 1998 Jan 2;273(1):58-65 PMID: 9417047
  31. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
    Arch Pharm Res. 2016 Nov;39(11):1597-1608 PMID: 27572156
  32. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
    Cancer Invest. 2009 Mar;27(3):244-50 PMID: 19194830
Full Text / Full Text
PMC full text available locally, click to read

Loading full text...

Article Info
Journal
Oncology letters
Abbr.
Oncol Lett
ISSN
1792-1074
DOI
10.3892/ol.2020.12420
Published
2021-02-00
Epub
2020-00-31
Pages
159
Language
English
Region
Greece
NLM ID
101531236
PMCID
PMC7798085
External Links
PubMed source DOI: 10.3892/ol.2020.12420 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2